Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 402
- Registration Number
- NCT03387163
- Locations
- πΊπΈ
Novartis Investigative Site, New York, New York, United States
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT03386474
- Locations
- π΅π·
Novartis Investigative Site, San Juan, Puerto Rico
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 301
- Registration Number
- NCT03379727
- Locations
- πΈπͺ
Novartis Investigative Site, Uppsala, Sweden
A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence
Phase 3
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Combination Product: Concept2 inhaler with patient applicationCombination Product: Concept2 inhaler
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT03379233
- Locations
- π³π±
Novartis Investigative Site, Zutphen, Netherlands
LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)
Phase 2
Withdrawn
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- Drug: Standard of care therapy
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03377426
- Locations
- π¬π·
Novartis Investigative Site, Athens, Greece
A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT03374657
- Locations
- πΈπͺ
Novartis Investigative Site, Stockholm, Sweden
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
- First Posted Date
- 2017-12-14
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT03373461
- Locations
- π¬π§
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT03372083
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection
Phase 2
Withdrawn
- Conditions
- HCMV Infection
- Interventions
- Biological: CSJ148Other: Placebo
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03369912
Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 337
- Registration Number
- NCT03369704
- Locations
- π―π΅
Novartis Investigative Site, Toshima-Ku, Tokyo, Japan
Β© Copyright 2025. All Rights Reserved by MedPath